Targeting Disease with the B-Tech™ Platform

ILiAD's B-Tech™ platform is a validated proprietary technology for developing therapeutics for the prevention and treatment of disease. BPZE1 is the most advanced ILiAD clinical candidate developed using the B-Tech™ platform.

Preclinical studies have demonstrated that BPZE1 protects against allergic airway disease and allergic dermatitis. ILiAD and its partners are conducting additional studies to determine if other B-Tech™ drug candidates provide a therapeutic benefit in asthma when administered after sensitization to common allergic antigens.

In addition, ILiAD is using the B-Tech™ platform to develop new clinical candidates to prevent allergic, neurologic and autoimmune disease due to subclinical B. pertussis colonizing infections.